{"id":"NCT01992549","sponsor":"Octapharma","briefTitle":"Study to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIII","officialTitle":"Extension Study for Patients Who Completed GENA-05 (NuProtect)- to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIII","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-04","primaryCompletion":"2018-12-27","completion":"2018-12-27","firstPosted":"2013-11-25","resultsPosted":"2019-12-17","lastUpdate":"2021-01-19"},"enrollment":48,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Severe Hemophilia A"],"interventions":[{"type":"BIOLOGICAL","name":"Human-cl rhFVIII","otherNames":[]}],"arms":[{"label":"Human-cl rhFVIII","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to collect long-term data on the inhibitor development rate of Human-cl rhFVIII in previously untreated patients with severe Hemophilia A.","primaryOutcome":{"measure":"Immunogenicity of Human-cl rhFVIII: Incidence of Inhibitors","timeFrame":"Maximum two years","effectByArm":[{"arm":"Human-cl rhFVIII","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"MALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":15,"countries":["United States","Canada","France","Georgia","India","Moldova","Poland","Ukraine","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":48},"commonTop":["Nasopharyngitis","Pyrexia","Cough","Varicella","Bronchitis"]}}